Deerfield Management Overview
- Investor Type
- Venture Capital
- Status
- Active
- Professionals
- 53
- Investments
- 239
- Portfolio
- 86
- Exits
- 138
Deerfield Management General Information
Description
Founded in 1994, Deerfield Management is an investment firm based in New York, New York. The firm seeks to invest in the healthcare, pharmaceutical, biotechnology, healthcare devices, supplies, healthcare services, life sciences, oncology and gaming sectors.
Contact Information
Website
Year Founded
1994
Investor Status
Actively Seeking New Investments
Trade Association
National Venture Capital Association (NVCA)
Primary Investor Type
Venture Capital
Other Investor Types
Growth/Expansion
Hedge Fund
Primary Office
- 780 Third Avenue
- 37th floor
- New York, NY 10017
- United States
+1 (212) 000-0000
Deerfield Management Investments (239)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Bridge Medicines | 12-Nov-2020 | Early Stage VC | 0000 | Drug Discovery | Generating Revenue | 0000000 00000000 |
| 0000000000 00000 0 | 10-Nov-2020 | 00000 00000 | 000.00 | Clinics/Outpatient Services | Generating Revenue | 000000 000000 00 |
| 0000000 0000000000 | 21-Oct-2020 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - Phase 2 | 000000 0000000000 00 |
| 00000000 000 | 21-Oct-2020 | 0000 | 00000 | Drug Discovery | Pre-Clinical Trials | |
| 00000 00000000 | 13-Oct-2020 | 00000 00000 | 000.00 | Biotechnology | Clinical Trials - Phase 1 | |
| 0-0000 | 22-Sep-2020 | 00000 00000 | 0000 | Therapeutic Devices | Clinical Trials - General | 000000 0000000000 00 |
| 00000 (0000000 000 | 09-Sep-2020 | 00000 00000 | 0000 | Managed Care | Generating Revenue | 000000 000000 00 |
| 00000000 000000 | 14-Aug-2020 | 00000 00000 | Medical Records Systems | Generating Revenue | 0000 00000000 | |
| Reprieve Cardiovascular | 04-Aug-2020 | Early Stage VC | 0000 | Diagnostic Equipment | Clinical Trials - General | 000000 0000000000 00 |
| Sema4 | 28-Jul-2020 | Later Stage VC | 00000 | Laboratory Services (Healthcare) | Generating Revenue | 000000 0000000000 00 |
Deerfield Management Exits (138)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Olema Oncology | 19-Nov-2020 | IPO | 00000 |
| 00000000 | 18-Nov-2020 | 0000000 000000 | |
| 00000 000000000 | 08-Oct-2020 | 000 | 0000 |
| 0000000 | 02-Oct-2020 | 000 | 0000 |
| 0000000 000000 | 25-Sep-2020 | 000 | 0000 |
| 0000000 | 21-Sep-2020 | 0000000000 | |
| 000000000 | 16-Sep-2020 | 000 | 0000 |
| 000000 0000000 | 06-Aug-2020 | 000 | 00000 |
| Annexon Biosciences | 24-Jul-2020 | IPO | 00000 |
| Nkarta Therapeutics | 13-Jul-2020 | IPO | 00000 |
Deerfield Management Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialDeerfield Management Team (72)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Jonathan Isler | Chief Financial Officer & Partner | New York, NY | |||
| Jana Jensen Ph.D | Chief Operating Officer, Deerfield Discovery and Development | New York, NY | |||
| Angelo Stornello | Chief Technology Officer | New York, NY | |||
| Alexander Karnal | Partner & Managing Director | 0 | 0 | New York, NY | |
| Alexis Cazé | Partner & Managing Director | New York, NY |
Deerfield Management Co-Investors (315)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| OrbiMed | 9 | 0 | 00 |
|
|
| GV | 0 | 0 |
|
|
|
| New Enterprise Associates | 0 | 0 |
|
|
|
| RA Capital Management | 0 | 0 | 0 |
|
|
| The Invus Group | 0 | 0 | 0 |
|
|